Application of Prmt5 as target spot in preparation of medicine for treating fatty liver disease

By targeting the Prmt5 gene or protease activity, using technologies such as small interfering RNA and lipid nanoparticles, the treatment problems of non-alcoholic fatty liver disease have been solved, significantly reducing liver fat accumulation and inflammation, and providing new therapeutic prospects.

CN119033937AInactive Publication Date: 2024-11-29SHANDONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411200554.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing drugs are not effective at non-alcoholic fatty liver disease, and lack specific target treatments, making it difficult to effectively reduce liver fat accumulation and inflammation.

Method used

By targeting the Prmt5 gene or protease activity, use Prmt5 gene expression inhibitors or protease activity inhibitors, including small interfering RNA, adeno-associated viruses and lipid nanoparticles, to reduce the expression of Prmt5 in the liver or inhibit its methyltransferase activity. This reduces fat accumulation and inflammation.

Benefits of technology

The study found that Prmt5 gene knockdown can improve liver function, reduce blood lipid levels, and delay the progress of liver vacuolation and fibrosis, providing a new target treatment plan for non-alcoholic fatty liver disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033937A_ABST
    Figure CN119033937A_ABST
Patent Text Reader

Abstract

The invention discloses application of Prmt5 as a target spot in preparation of a medicine for treating fatty liver diseases, belongs to the technical field of biological medicines, and particularly relates to application of a reagent for inhibiting Prmt5 gene expression or Prmt5 protease activity in preparation of a medicine for treating non-alcoholic fatty liver diseases. The invention finds that the liver Prmt5 gene knock-down can improve the liver function and glucose tolerance of high-fat diet fed mice, reduce the blood fat level and delay the liver vacuolation lesion, lipid deposition, hepatitis and liver fibrosis processes. Liver targeting Prmt5 gene knock-down lipid nanoparticles and Prmt5 protease activity small-molecule inhibitors which are packaged by taking small interfering RNA as a raw material can also achieve the effect of improving the liver function of mice. Therefore, as a new target for preventing and treating the non-alcoholic fatty liver disease, the PRMT5 has an important application prospect in treatment of the non-alcoholic fatty liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to the application of Prmt5 as a target in the preparation of a drug for treating fatty liver disease. Background Art

[0002] Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide. It has become the main cause of end-stage liver disease (such as cirrhosis and liver cancer), seriously affecting and threatening human health. Current studies believe that NAFLD is mainly caused by excessive intake of lipids (mainly triglycerides TG) that accumulate in hepatocytes, inducing lipotoxicity and leading to oxidative stress, metabolic disorders, inflammatory activation and other pathological processes in hepatocytes. Currently, commonly used clinical drugs are not specifically for the treatment of non-alcoholic fatty liver disease, such as liraglutide, an insulin peptide 1-like receptor agonist for the treatment of type II diabetes, ursodeoxycholic acid, a gallstone dissolving drug, and orlistat, a gastrointestinal esterase inhibitor for the treatment of obesity. Therefore, taking liver metabolism as a direct entry point and finding effective therapeutic targets are of great significance for the development and treatment of NAFLD drugs.

[0003] The human PRMT5 or mouse Prmt5 gene is located on their respective autosomes 14. The protein transcribed and translated has 637 amino acids, and the sequence conservation between species is 98%. Prmt5 belongs to type II arginine methyltransferase, which catalyzes the symmetrical dimethylation modification of arginine at specific sites of nuclear histones and cytoplasmic proteins, and can enrich the diversity of protein localization, homeostasis, activity, and functional changes. Research on Prmt5 believes that it can participate in the regulation of lipid metabolism, such as catalyzing the symmetrical dimethylation modification of arginine at position 321 of cholesterol regulatory element binding protein SREBP1a (sterol regulatory element-binding proteins, SREBP), resulting in reduced phosphorylation modification of SREBP1a and separation from the binding of E3 ubiquitin ligase FBW7, and reduced degradation of SREBP1a protein, achieving the effect of promoting lipid synthesis. At present, there are no related patent reports targeting Prmt5 gene or protein for the treatment of non-alcoholic fatty liver disease. Summary of the invention

[0004] In order to overcome the shortcomings of the prior art, the present invention provides the use of Prmt5 as a target in the preparation of a drug for treating fatty liver disease, so as to enrich the strategy of liver-targeted drugs in the clinical treatment of non-alcoholic fatty liver disease. In order to achieve the above purpose, the present invention provides the following technical solutions:

[0005] Application of Prmt5 as a target in the preparation of drugs for treating fatty liver disease.

[0006] The drug is a Prmt5 gene expression inhibitor or a Prmt5 protease activity inhibitor.

[0007] Furthermore, the present invention provides the use of Prmt5 as a target in the preparation of a drug for treating non-alcoholic fatty liver disease.

[0008] In an embodiment of the present invention, the non-alcoholic fatty liver disease is non-alcoholic fatty liver disease caused by excessive accumulation of fat in liver cells.

[0009] In an embodiment of the present invention, the drug reduces abnormal fat accumulation in the liver, hepatitis and liver fibrosis levels by regulating Prmt5 gene expression or inhibiting Prmt5 protease activity.

[0010] In the embodiment of the present invention, the drug targets the Prmt5 gene and reduces the expression of Prmt5 at the protein level.

[0011] In an embodiment of the present invention, the drug targets the Prmt5 protein and inhibits the methyltransferase activity of the Prmt5 protein.

[0012] In an embodiment of the present invention, the drug includes small interfering RNA targeting Prmt5 gene, adeno-associated virus targeting Prmt5 gene of hepatocytes in vivo, lipid nanoparticles targeting Prmt5 gene of hepatocytes in vivo, or small molecule compounds that inhibit Prmt5 protease activity.

[0013] In an embodiment of the present invention, the drug uses the Prmt5 gene inhibitor or the Prmt5 protease activity inhibitor as a single ingredient; or the drug uses the Prmt5 gene inhibitor or the Prmt5 protease activity inhibitor as a raw material and adds pharmaceutically acceptable excipients.

[0014] In an embodiment of the present invention, the medicine is in the form of tablets, granules, capsules or injections.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention provides the use of Prmt5 as a target in the preparation of a drug for treating fatty liver disease. The present invention found that knocking down the liver Prmt5 gene can improve the liver function and glucose tolerance of mice fed a high-fat diet, reduce blood lipid levels, and delay the progression of liver cavitation lesions, lipid deposition, hepatitis and liver fibrosis. Lipid nanoparticles and small molecule inhibitors of Prmt5 protease activity that target the liver and knock down the Prmt5 gene packaged with small interfering RNA as raw materials can also achieve the effect of improving the liver function of mice. Therefore, PRMT5, as a new target for the prevention and treatment of non-alcoholic fatty liver disease, has important application prospects for the treatment of non-alcoholic fatty liver disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0018] Figure 1 It is the experimental grouping and experimental flow chart in Example 1 of the present invention.

[0019] Figure 2 This is the result of in vivo imaging of mice using shRNA / AAV8 adeno-associated virus in Example 1 of the present invention.

[0020] Figure 3 This is the knockdown efficiency result of shRNA / AAV8 adeno-associated virus in mouse liver in Example 1 of the present invention.

[0021] Figure 4 This is the result of the effect of liver-targeted Prmt5 gene knockdown on serum aspartate aminotransferase in mice induced by a high-fat diet in Example 1 of the present invention.

[0022] Figure 5 This is the result of the effect of liver-targeted Prmt5 gene knockdown on serum alanine aminotransferase in mice induced by a high-fat diet in Example 1 of the present invention.

[0023] Figure 6 This is the result of the effect of liver-targeted Prmt5 gene knockdown on serum triglycerides in mice induced by a high-fat diet in Example 1 of the present invention.

[0024] Figure 7 This is the result of the effect of liver-targeted Prmt5 gene knockdown on serum total cholesterol in mice induced by a high-fat diet in Example 1 of the present invention.

[0025] Figure 8 This is the result of the effect of liver-targeted Prmt5 gene knockdown on high-fat diet-induced glucose tolerance in mice in Example 1 of the present invention.

[0026] Fig. 9 This is the HE staining result of liver tissue sections of liver-targeted Prmt5 gene knockdown mice induced by a high-fat diet in Example 1 of the present invention.

[0027] Fig.10 This is the Oil Red O staining result of liver tissue sections of liver-targeted Prmt5 gene knockdown mice induced by a high-fat diet in Example 1 of the present invention.

[0028] Fig.11 This is the result of the effect of liver-targeted Prmt5 gene knockdown in Example 1 of the present invention on the expression of genes related to liver inflammation and fibrosis induced by a high-fat diet in mice.

[0029] Fig.12 It is the experimental grouping and experimental flow chart in Example 2 of the present invention.

[0030] Fig.13 This is the organ distribution of the lipid nanoparticles encapsulating siPrmt5 in Example 2 of the present invention in mice.

[0031] Fig.14 This is the result of the effect of serum aspartate aminotransferase on MCD-induced non-alcoholic fatty liver disease mice after drug treatment in Example 2 of the present invention.

[0032] Fig.15 This is the result of the effect of serum alanine aminotransferase on MCD-induced non-alcoholic fatty liver disease mice after drug treatment in Example 2 of the present invention.

[0033] Fig.16 This is the HE staining result of liver tissue sections of MCD-induced non-alcoholic fatty liver mice after drug treatment in Example 2 of the present invention. DETAILED DESCRIPTION

[0034] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0035] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0036] Example 1: Effects of liver-specific knockdown of Prmt5 on high-fat diet-induced non-alcoholic steatohepatitis in mice

[0037] The experimental animals were 7-week-old C57BL / 6Jpt male mice, weighing about 20g, purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The sterile packaged mice received were moved to the SPF animal center. After passing the quarantine of the center, the old cages were removed, replaced with new cages and transferred to the breeding room for subsequent experiments. The mice were randomly divided into cages of 5 / cage and adaptively raised for one week. The experiment began when the mice were 8 weeks old. At the beginning of the experiment, the AAV8 serotype adeno-associated virus with the TBG liver-specific promoter shPrmt5 / shNC was injected through the tail vein of the mice. After two weeks of injection, the virus was allowed to exert a stable knockdown effect, and the experimental mice were fed with high-fat refined grain feed.

[0038] The experimental groups are as follows:

[0039] Wild control group: The mice were fed a high-fat diet containing 45% fat, and were free to drink sterile purified water.

[0040] Prmt5 gene knockdown group: mice were fed a high-fat diet containing 45% fat, and were free to drink sterile purified water.

[0041] Experimental process and content (see attached) Figure 1 shown):

[0042] (1) Construction of liver-specific Prmt5 knockdown mice

[0043] An 8-week-old mouse was placed in the restraint of the tail vein injection instrument, and the mouse's mouth and nose were placed in the breathing hole at the front end of the restraint to prevent suffocation. The instrument injection light was turned on to find the veins on both sides of the tail, and a needle was inserted into the vein near the tip of the tail. 100 μl of 5×10E11vg virus was pushed into the vein. After 24 weeks of high-fat diet, in vivo imaging technology was used to confirm the liver targeting level of AAV8 virus, and Western Blotting technology was used to detect the knockdown efficiency of Prmt5.

[0044] Regarding in vivo imaging, first, a 15mg / ml D-luciferin potassium salt solution was intraperitoneally injected at 10μl / g mouse body weight. D-luciferin potassium salt is a common substrate of firefly luciferase. It undergoes oxidative decarboxylation reaction under the action of firefly luciferase to emit blue-green bioluminescence with a wavelength of about 560nm. The virus used in this experiment can express firefly luciferase to indicate the distribution of the virus in the body. Then, the mouse was anesthetized with inhaled isoflurane. After anesthesia, the mouse was placed on the imaging pad of the host of the small animal in vivo optical imaging system, and the distribution of bioluminescence in vivo was photographed in the automatic exposure mode.

[0045] (2) Liver function index detection

[0046] After fasting for 8 hours, the mice were blooded from the tail vein into a clean 1.5 ml centrifuge tube. The blood was allowed to stand at room temperature for 1 hour, then centrifuged at 2000 rpm for 10 minutes, and the upper clear light yellow serum was collected for blood lipid testing. The detection indicators include alanine aminotransferase (glutamic pyruvic transaminase, GPT also known as ALT) and aspartate aminotransferase (glutamic oxaloacetic transaminase, GOT also known as AST). The detection kits used were all from Nanjing Jiancheng Bioengineering Institute. Specifically, the serum to be tested was first diluted 10 times with PBS and stored on ice at low temperature for use, and the matrix solution in the kit was preheated at 37°C for use. Pipette 20 μl of pre-warmed matrix solution into a 96-well plate, then pipette 5 μl of diluted serum into the matrix solution at the bottom of the plate, repeatedly pipette and mix, and react at 37°C for 30 minutes. After the incubation, add 20 μl of 2,4-dinitrophenylhydrazine to each well, pipette and mix, and react at 37°C for 20 minutes. Finally, add 200 μl of 0.4 mol / L sodium hydroxide solution to each well and shake gently horizontally for color development. After standing at room temperature for 15 minutes, measure the OD with an enzyme reader 510 Read the value, check the standard curve, and calculate the corresponding GPT activity unit. The final enzyme activity is the measured enzyme activity value multiplied by the serum dilution multiple.

[0047] (3) Blood lipid test

[0048] After fasting for 8 hours, blood was collected from the tail vein of mice into a clean 1.5 ml centrifuge tube. The blood was left to stand at room temperature for 1 hour, then centrifuged at 2000 rpm for 10 minutes, and the upper clear light yellow serum was collected for blood lipid testing. The test indicators included triglyceride (TG) and total cholesterol (T-CHO), and the test kits used were all from Nanjing Jiancheng Bioengineering Institute.

[0049] Specifically, 250 μl of the working solution was added to a 96-well plate, and then 2.5 μl of the serum to be tested or distilled water or the calibrator in the kit was added to the corresponding wells. The well plate was placed in a 37°C incubator for 10 minutes, and the OD of each well was measured by an ELISA reader. 546 The triglyceride content was calculated according to the following formula:

[0050] Triglyceride content (mmol / L) = (A 样品孔 -A 空白孔 ) / (A 标准孔 -A 空白孔 )×C 标准

[0051] Pipette 250 μl of working solution into a 96-well plate, then add 2.5 μl of serum to be tested or distilled water or the calibrator in the kit into the corresponding wells, incubate the wells in a 37°C incubator for 10 minutes, and measure the OD of each well with an enzyme-labeled instrument. 500 The triglyceride content was calculated according to the following formula:

[0052] Cholesterol content (mmol / L) = (A 样品孔 -A 空白孔 ) / (A 标准孔 -A 空白孔 )×C 标准

[0053] (4) Blood sugar and glucose tolerance test

[0054] Mice fed a high-fat diet for 22 weeks were significantly obese, and the blood glucose and glucose tolerance of mice were tested at this time. The mice were fasted for 8 hours, and they were free to drink water during this period. Before starting the measurement, the blood glucose test strip was inserted into the blood glucose meter, and about 5μl of venous blood was collected from the tail tip and dripped onto the blood glucose test strip. The blood glucose measurement was completed when the instrument displayed the blood glucose value. Subsequently, the mouse glucose tolerance test was performed, and a sterile glucose solution with a concentration of 0.2g / mL was injected intraperitoneally at a rate of 1g / kg mouse body weight. Blood was collected from the tail tip at 15 minutes, 30 minutes, 60 minutes, and 120 minutes after the injection. The blood glucose of the mice was tested using a blood glucose test strip, and the blood glucose-time curve was drawn and the area under the curve (Area under curve, AUC) was calculated.

[0055] (5) HE staining to detect the degree of liver cavitation

[0056] The middle lobe of the mouse liver was taken, fixed with paraformaldehyde, dehydrated, embedded in paraffin, and sliced ​​to obtain a 4um thick paraffin section of the mouse liver. The sections were placed on a metal dewaxing rack and placed in a 60°C oven for 1 hour, followed by dewaxing and hydration with the following reagents: xylene (15 minutes) - xylene (15 minutes) - 100% alcohol (5 minutes) - 100% alcohol (5 minutes) - 100% alcohol (5 minutes) - 90% alcohol (5 minutes) - 70% alcohol (5 minutes) - distilled water (5 minutes). The sections were placed in hematoxylin staining solution and stained at room temperature for 5 minutes. The sections were taken out of the slice rack and placed in a 0.5% hydrochloric acid ethanol solution for differentiation for 3 seconds. The sections were quickly taken out and placed in weakly alkaline tap water, and rinsed with running water until the nuclei turned blue. The sections were then placed in eosin staining solution and stained at room temperature for 30 seconds. The excess stain was rinsed off with tap water and placed in a ventilated place to dry. The sections were immersed in xylene for 5 minutes to make them transparent and dehydrated, dried in a fume hood, and photographed after being sealed with neutral resin. The nuclei in the tissues were stained blue by hematoxylin, the cytoplasm was stained light pink by eosin, and the areas with vacuolated lesions were not stained and were white.

[0057] (6) Oil red O staining to detect lipid deposition in liver tissue

[0058] Preparation of Oil Red O stock solution: weigh 0.5 g of Oil Red O powder, add 100 ml of isopropanol, seal the bottle and place in a 60°C water bath to dissolve for more than 2 hours, and store at 4°C for a long time away from light.

[0059] Preparation of Oil Red O working solution: Mix Oil Red O stock solution and distilled water in a volume ratio of 3:2, warm in a 60℃ water bath for more than 2 hours, filter while hot and dry to room temperature, then it can be used for dyeing.

[0060] Staining process: The right posterior lobe of the mouse liver was taken, fixed and dehydrated with paraformaldehyde, and then cut on ice to obtain frozen sections of the mouse liver with a thickness of 10um. The sections were stored at -20℃. Before formal staining, the frozen sections were taken out from -20℃, placed at room temperature for about 5 minutes to warm them up, and the sections were placed on the staining rack and placed in PBS solution for 10 minutes to wash away the OCT embedding agent. Then the slice rack was immersed in 60% isopropanol solution for 5 minutes, placed in Oil Red O working solution for 10 minutes, and the staining rack was taken out and immersed in 60% isopropanol solution to wash away the excess dye. The sections were rinsed with double distilled water, and hematoxylin was used for re-staining for 5 minutes. The slice rack was taken out and placed in 0.5% hydrochloric acid ethanol solution for differentiation for 3 seconds, and quickly taken out and placed in weakly alkaline tap water, and rinsed with running water to return to blue. After staining, the slides were immediately sealed with glycerol or water, and they should not be squeezed or displaced after sealing. Under the microscope, the cell nuclei in the tissue were stained blue by hematoxylin, and the lipid droplets were stained orange by Oil Red O.

[0061] (7) qPCR detection of liver inflammation and fibrosis-related gene expression levels

[0062] RNA was extracted from fixed areas of the mouse liver tissue, and after reverse transcription, the gene expression level was detected using qPCR (Quantitative Real-time PCR) technology. Specifically, about 0.1g of fresh left lateral lobe midline area tissue was taken into a 1.5ml centrifuge tube, 300μl of lysis buffer in the RNA rapid extraction kit was added, two grinding beads / tube were added, and the EP tube was placed symmetrically in a tissue grinder precooled at 4℃, with grinding parameters of 40HZ 25s, 0HZ 15s; the cycle was repeated 4-6 times until the tissue was fully lysed. The tissue homogenate was transferred to a low-temperature centrifuge and centrifuged at 12000g for 2 minutes. The supernatant was transferred to a new 1.5ml centrifuge tube. An equal volume of anhydrous ethanol was added to the supernatant and inverted to mix thoroughly. The liquid was then transferred to an RNA purification column with a 2ml collection tube at the bottom. After centrifugation at 4000g for 1 minute at room temperature, the liquid in the 2ml collection tube was poured out. 500μl of WASH buffer provided in the kit was added to the RNA purification column. After centrifugation at 12000g for 1 minute at room temperature, the liquid in the 2ml collection tube was poured out. The RNA column was returned to the collection tube and centrifuged once to completely remove the residual Wash buffer. The RNA column was taken out and placed in a clean 1.5ml centrifuge tube without RNase. After opening the lid and drying for 1 minute, 50μl of Elution buffer provided in the kit was added and allowed to stand for 2 minutes. Centrifugation at 12000g for 1 minute at room temperature. The eluted RNA was measured for concentration, and 500ng RNA / 20μl reaction system was added for reverse transcription according to the reagent instructions of Nanjing Novogene (Cat. No. R323). The cDNA obtained after reverse transcription was prepared in an eight-tube strip with a reaction system of 10 ng cDNA / 20 μl according to the reagent instructions of SYBR Green master Mix (Cat. No. A25742) from Applied biosystems. The eight tube strips were placed in turn in the Applied biosystems QuantStudio3 real-time fluorescence quantitative PCR instrument for real-time PCR reaction, and the changes in liver fibrosis-related genes were calculated based on the CT values.

[0063] Experimental results:

[0064] According to the attached Figure 1 The liver-specific Prmt5 gene knockdown mice were constructed, grouped, and other related experiments were performed as shown in the attached figure. Figure 2 The results showed that the AAV8 virus injected intravenously into mice specifically accumulated and expressed in the liver tissue. Western blot experiments were further performed on protein samples of liver tissue lysates of the corresponding mice. Figure 3The results showed that the Prmt5 protein level in the liver of mice injected with shPmrt5 / AAV8 virus was significantly lower than that of the control virus. The above results indicate that the liver-specific knockdown Prmt5 mouse was successfully constructed.

[0065] AST and ALT are common indicators for testing liver function. Liver damage or liver disease can cause their indicators to rise. Figure 4 and attached Figure 5 The results showed that the serum enzyme activity of mice injected with shPrmt5 / AAV8 was lower than that of wild-type control mice. The detection of TG and TC in the blood of mice showed that the blood lipid levels of mice injected with shPrmt5 / AAV8 were lower than those of the control group (e.g. Figure 6 , Figure 7 At the same time, the Prmt5 knockdown group mice were highly sensitive to glucose, and their ability and rate of glucose metabolism were faster than those of the wild-type control group (as shown in Figure 2A). Figure 8 The above results show that liver-specific knockdown of Prmt5 can delay liver damage, reduce blood lipid levels, and improve glucose tolerance, thus indicating that knockdown of the Prmt5 gene has the effect of delaying the development of non-alcoholic fatty liver disease.

[0066] Histomorphological staining can more intuitively show the liver lesions. Fig. 9 The results showed that the liver tissue of wild-type control mice fed a high-fat diet for 24 weeks showed extensive ballooning degeneration, and the cytoplasmic area of ​​hepatocytes was reticular. The degree of vacuolization in the liver tissue of shPrmt5 mice was significantly lower than that of wild-type mice. Fig.10 The oil red O staining shown shows that the size and area of ​​lipid droplets in the liver tissue of shPrmt5 mice are much smaller than those in the wild-type control mice. As the lesions worsen, the liver will show signs of inflammation and fibrosis. qPCR detection of inflammation and fibrosis-related gene levels also shows that reducing Prmt5 levels can delay the progression of hepatitis and liver fibrosis (such as Fig.11 The above tissue morphological results indicate that knocking down the Prmt5 gene can improve the symptoms of non-alcoholic fatty liver disease.

[0067] Example 2: Effects of lipid nanoparticle-encapsulated small interfering RNA or small molecule inhibitors on non-alcoholic fatty liver disease induced by a methionine-choline deficient diet

[0068] The experimental animals were 8-week-old C57BL / 6Jpt male mice weighing about 25 g, purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The sterile packaged mice received were moved to the SPF animal center. After passing the quarantine of the center, the old cages were removed, replaced with new cages and transferred to the breeding room for subsequent experiments. In this Example 2, a methionine and choline deficient diet (MCD) was used to induce fatty liver, and then RNA drugs or small molecule drugs were given for treatment.

[0069] Methionine is an essential amino acid that provides methyl groups in the body to synthesize choline. Choline is a component of substances such as lecithin and acetylcholine. Choline deficiency prevents fat in the liver from synthesizing phospholipids and transporting them out, which leads to fat deposition in the liver to form fatty liver. Mice fed with MCD can show signs of non-alcoholic fatty liver disease in a relatively short period of time. In addition to using viral infection technology to edit designated genes in clinical practice, lipid nanoparticles (LNP) encapsulating RNA are an effective RNA drug delivery system that is not prone to immune rejection. After entering the blood, LNP can bind to free APoE in the blood, and APoE binds to the APoE binding receptors unique to the surface of liver parenchymal cells, promoting the fusion of the LNP lipid structure with the liver cell membrane, and the RNA encapsulated therein enters the cell to exert its therapeutic effect. At the same time, LNP can protect the RNA encapsulated therein from degradation, thereby improving its bioavailability. At present, mature LNP drugs have entered clinical treatment through clinical trials. For example, Onpattro can silence the expression of transthyretin (TTR) mRNA in hepatocytes, reduce TTR protein levels, and reduce the accumulation of amyloid deposits in peripheral nerves. It is used to treat adult patients with peripheral polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR). In the field of medicinal chemistry research, a variety of highly potent and specific PRMT5 small molecule inhibitors have been synthesized. They have been proven to have therapeutic effects on liver cancer, breast cancer, glioma, etc., but they have not been used in the treatment of non-alcoholic fatty liver disease.

[0070] In this Example 2, an MCD diet was used to induce fatty liver, and then RNA / LNP drugs or small molecule drugs were administered for treatment.

[0071] The experimental groups are as follows:

[0072] Healthy diet group: Wild-type mice were fed with normal growth feed and allowed to drink sterile purified water freely. No drugs were injected during the whole experiment.

[0073] MCD disease group: wild-type mice were fed with MCD diet, mice were free to drink sterile purified water, and control solution was injected regularly.

[0074] MCD-LNP treatment group: Wild-type mice were fed MCD feed, mice were free to drink sterile purified water, and were regularly injected with siRNA / LNP drugs.

[0075] MCD-GSK591 treatment group: Wild-type mice were fed MCD feed, mice were free to drink sterile purified water, and were regularly injected with GSK591 small molecule drugs.

[0076] The experimental process and content are attached. Fig.12 Specifically, at the beginning of the experiment, after the mice were fed with MCD feed for 10 days, 10ug siPrmt5 LNP (containing CY5 fluorescent probe) / mouse, or 1mg small molecule inhibitor GSK591 / mouse, or an equal volume of control solvent were injected into the corresponding mice. The injection treatment was given once every four days, for a total of 4 injections, and the MCD feed was continued during the period. The mice on a healthy diet were not injected with drugs throughout the whole process. When the experiment was carried out to the 21st day, blood was collected from the tail vein, and the upper layer of transparent serum was collected by centrifugation. The liver function indicators of each group of mice were tested, and the liver tissue of the mice was made into paraffin sections for histomorphological HE staining.

[0077] Regarding the in vivo distribution of LNP drugs, we euthanized the mice 4 hours after the injection of control solvent or LNP drugs, dissected the heart, lungs, liver, kidneys and spleen of the mice, rinsed the surface blood stains with pre-cooled PBS, absorbed the surface moisture with filter paper, and placed the organs on the small animal living imaging pad according to groups, and selected CY5 signal for drug tissue distribution imaging.

[0078] Experimental results:

[0079] As attached Fig.13 As shown in the figure, obvious CY5 fluorescence signals were detected in mice injected with siPrmt5 / LNP drugs, and the CY5 signals were mainly concentrated in the liver, indicating that the LNP drug targeted the liver to play a gene regulatory role. The transaminase levels of mice treated with LNP or small molecule inhibitor GSK591 for 16 days were lower than those of the MCD disease group (see the attached results). Fig.14 , Attachment Fig.15 ), the degree of vacuolization in the liver tissue of mice in the treatment group was reduced (see Appendix Fig.16 ).

[0080] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Application of Prmt5 as a target in the preparation of drugs for the treatment of fatty liver disease.

2. The use according to claim 1, characterized in that: The drug is a Prmt5 gene expression inhibitor or a Prmt5 protease activity inhibitor.

3. Application of Prmt5 as a target in the preparation of drugs for the treatment of non-alcoholic fatty liver disease.

4. The use according to claim 3, characterized in that: The non-alcoholic fatty liver disease is caused by excessive accumulation of fat in liver cells.

5. The use according to claim 3, characterized in that: The drug reduces abnormal fat accumulation in the liver, hepatitis and liver fibrosis levels by regulating Prmt5 gene expression or inhibiting Prmt5 protease activity.

6. The use according to claim 3, characterized in that: The drug targets the Prmt5 gene and reduces the expression of Prmt5 at the protein level.

7. The use according to claim 3, characterized in that: The drug targets the Prmt5 protein and inhibits the methyltransferase activity of the Prmt5 protein.

8. The use according to claim 3, characterized in that: The drug includes small interfering RNA targeting the Prmt5 gene, adeno-associated virus targeting the Prmt5 gene of hepatocytes in vivo, lipid nanoparticles targeting the Prmt5 gene of hepatocytes in vivo, or a small molecule compound that inhibits the protease activity of Prmt5.

9. The use according to any one of claims 1 to 8, characterized in that: The drug is made of a Prmt5 gene inhibitor or a Prmt5 protease activity inhibitor as a single component; or the drug is made of a Prmt5 gene inhibitor or a Prmt5 protease activity inhibitor as a raw material and a pharmaceutically acceptable excipient is added.

10. The use according to claim 9, characterized in that: The medicine is in the form of tablets, granules, capsules or injections.

Citation Information

Patent Citations

  • Application of NAT10 as target spot in treatment of metabolism-related fatty liver disease

    CN118045189A

  • Application of reagent for inhibiting expression quantity of Fmrp protein in hepatocytes in preparation of medicine for treating non-alcoholic fatty liver disease

    CN118161613A

  • Methods and compositions of in vivo engineering of t-cells to Anti-inflammatory cells and therapeutic applications there of

    WO2024145643A1